| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
When paired with entecavir or tenofovir, vonafexor (EYP001) has additive effects that significantly reduce HBV DNA, HBsAg, and HBeAg secretion in HepaRG cells by inhibiting the HBV replication cycle [3].
|
|---|---|
| References |
|
| Molecular Formula |
C19H15CL3N2O5SEXACTMASS
|
|---|---|
| Molecular Weight |
489.7568
|
| Exact Mass |
487.976
|
| CAS # |
1192171-69-9
|
| Related CAS # |
1192171-69-9;
|
| PubChem CID |
67202717
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.604±0.06 g/cm3(Predicted)
|
| Boiling Point |
680.5±65.0 °C(Predicted)
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XLGQSYUNOIJBNR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
|
| Chemical Name |
4-chloro-5-[4-(2,6-dichlorobenzene-1- sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid
|
| Synonyms |
VonafexorEyp001
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~170.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0418 mL | 10.2091 mL | 20.4182 mL | |
| 5 mM | 0.4084 mL | 2.0418 mL | 4.0836 mL | |
| 10 mM | 0.2042 mL | 1.0209 mL | 2.0418 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06425055 | RECRUITING | Drug: Vonafexor | Alport Syndrome | Enyo Pharma | 2024-07-05 | Phase 2 |
| NCT03812029 | COMPLETED | Drug: Vonafexor Other: Placebo |
Non-alcoholic Steatohepatitis | Enyo Pharma | 2019-01-30 | Phase 2 |
| NCT04465916 | TERMINATED | Drug: EYP001a Drug: Placebo |
Hepatitis B, Chronic | Enyo Pharma | 2020-05-12 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
